Inactive Instrument

Highlights CytRx Corporation OTC Bulletin Board

Equities

End-of-day quote OTC Bulletin Board Other stock markets
-	-

Mar. 27	LadRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 11	Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

LadRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol	Jan. 11	DJ
LadRx Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
LadRx Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Reverse Split: 1 of 100	23-05-16	FA
LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
LadRx Corporation has filed an IPO in the amount of $24 million.	23-04-14	CI
LadRx Highlights Patent Issued for Its LADR Technology	23-03-27	CI
LadRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
LadRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
Investor Presentation: November 2022	22-11-17	PU
LadRx Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Investor Presentation: September 2022	22-09-26	PU
Investor Presentation: August 2022	22-09-10	PU
LadRx Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Investor Presentation: July 2022	22-07-14	PU
CytRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
CytRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-23	CI
CytRx Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
CytRx Corporation Highlights ImmunityBio, Inc.'s Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment	21-10-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights CytRx Corporation OTC Bulletin Board

Equities

Highlights

Filters